| Officer | Age | Joined | 2025 pay | Source |
|---|---|---|---|---|
|
Richard F. Pops
Also a director
Chief Executive Officer and Chairman of the Board
|
64 | Not stated | $7,915,081 | |
|
Blair C. Jackson
President & CEO, Alkermes plc
Title from the Form 4 dated Aug 5, 2026
|
53 | 1999 | $4,030,905 | |
|
Joshua Reed
Senior Vice President, Chief Financial Officer
|
53 | 2025 | $3,797,074 | |
|
Jackson
President
|
Not stated | Not stated | Not reported | |
|
David J. Gaffin
EVP, CLO, Alkermes, Inc.
Title from the Form 4 dated Nov 3, 2026
|
54 | 2005 | $3,470,083 | |
|
Craig C. Hopkinson
EVP R&D, Chief Medical Officer
Title from the Form 4 dated Sep 1, 2026
|
58 | Not stated | $3,617,908 | |
|
C. Todd Nichols
Senior Vice President, Chief Commercial Officer
|
57 | Not stated | $2,790,694 | |
|
Samuel Joseph Parisi
VP, Finance (Interim PAO)
Title from the Form 4 dated May 29, 2026
|
Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 6, 2026 · updated by the 8-Ks of Aug 3, 2026 and Sep 16, 2026
| Director | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|
|
Richard F. Pops
Board chair, CEO
|
2011
15 years
|
Not independent |
Financial Operating
|
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) | Paid as CEO | |
|
Shane M. Cooke
|
2018
8 years
|
Independent |
Audit and Risk · Chair
|
Prothena Corporation plc (Nasdaq: PRTA) | $484,751 | |
|
Richard B. Gaynor
|
2019
7 years
|
Independent |
Compensation · Chair
|
Zai Lab Limited (Nasdaq: ZLAB) | $474,014 | |
|
Cato T. Laurencin
|
2021
5 years
|
Independent |
Financial Operating
|
MiMedx Group, Inc. (Nasdaq: MDXG) | Not stated | |
|
Nancy S. Lurker
|
2024
2 years
|
Independent |
Compensation
Nominating and Corporate Governance · Chair
|
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), Collegium Pharmaceutical, Inc. (Nasdaq: COLL) | $476,212 | |
|
Brian P. McKeon
|
2020
6 years
|
Independent |
Compensation
Financial Operating · Chair
Nominating and Corporate Governance
|
Dentsply Sirona Inc. (Nasdaq: XRAY) | $491,333 | |
|
Nancy L. Snyderman
|
2016
10 years
|
Independent |
Audit and Risk
Financial Operating
|
None stated | $479,135 | |
|
Christopher I. Wright
|
2022
4 years
|
Independent |
Audit and Risk
Compensation
|
None stated | Not stated | |
|
Jackson
Joined Aug 1, 2026
|
- | - |
Financial Operating Committee
|
- | - | |
|
Anne C. Whitaker
Joined Sep 14, 2026
|
- | - | - | - | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 6, 2026 states there were none.
Read it in the proxyLoading...